Development of new Nanoplatforms for the treatment and prevention of Atherosclerosis

作者
Valentina Di Francesco
出处
期刊: [University of Genoa]
标识
DOI:10.15167/di-francesco-valentina_phd2021-05-12
摘要

Over the last decade, many studies suggest that inflammation has an important role in atherosclerosis progression and development. In the last years, old cheaper drugs, Methotrexate (MTX) and Colchicine (COL) were considered to treat this pathology due to their anti-inflammatory effects. MTX, a conventional chemotherapeutic medicine currently representing the first-line option in inflammatory diseases like rheumatoid arthritis (RA) and psoriatic arthritis, was proposed in the clinical trial Cardiovascular Inflammation Reduction Trial (CIRT). Even though many studies have demonstrated this drug's beneficial activity on animals/patients with atherosclerosis, the clinical trial failed. Col is known for its therapeutic use in gout and Familial Mediterranean Fever (FMF). In these patients, it was noticed a reduction of myocardial infarctions after the use of Colchicine. Its effect is associated with a stronger effect in the inhibition of inflammasome activation and IL-1? secretion. These observations are at the base of different clinical trials like Low-Dose Colchicine (LoDoCo), A second Low Dose Colchicine (LoDoCo2), Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI). In general, their clinical use is limited by their several side effects and, furthermore, in MTX?s case is even more difficult due to its poor bioavailability and solubility in biological fluids. Taking this into account, nanomedicine might become a valid ally in furnishing potent tools to ease combined treatment and increase drug accumulation at the target site. Thus, this work aims to propone nanoparticles, polymeric, and lipid to improve the stability and solubility of encapsulated cargos, promote transport across membranes, and prolong circulation times to increase safety and efficacy. Here, it was proposed two different strategies for modifying the methotrexate by conjugating the DSPE and PEG. The prodrugs obtained (DSPE-MTX and PEG-MTX) were used to synthesize liposomes, including one or both of them. Physiochemical features were tested. The DSPE-MTX was selected (due to the instability at pH 6.8 of the system) and delivered by liposomes (MTX-LIP) and spherical polymeric nanoparticles (MTX-SPNs). Both nanoparticle formulations presented similar features. For the lipidic nanoparticles, the size is 174�2 nm (PdI: 0.15 � 0.0007), and Zeta Pot -48 � 0.02 mV; for the polymeric nanocarriers, the size is 208�2 nm (PdI: 0.15 � 0.02), and Zeta Pot 45.8?�?0.02 mV. MTX encapsulation efficiency (EE%) 70�5% for Lip-MTX and 1.5�0.2% for SPNs-MTX. Foam cells were obtained by treating rat bone marrow-derived monocytes (BMDM) with oxLDL. The treatment with the two nanoformulations was able to reverse foam cells maturation into macrophages. Both MTX-LIP and MTX-SPNs decreased cholesterol amounts after 24 hours in BMDM. The efficacy of the treatment was also proved by gene expression analysis. RT-PCR showed that the CD36 and SRA-1 gene expression (regulating oxLDL influx) was minimal. The reverse cholesterol transporter (ABCA1) in foam cells treated with the nanoformulations was inducing a 2-fold compare the CTRL. MTX-LIP and MTX-SPNs also reduced inflammatory gene expression (IL-6, IL-1?, and TNF?). MTX-LIP was used in vivo in a murine model of atherosclerosis. ApoE-/- mice, fed with a high-fat diet for 28 days, were treated for 4 weeks (once every three days) with MTX-LIP. Plaque burden was measured, revealing a reduction in plaque area for the treated mice. These results influenced a new line of thinking; it could be possible to boost the liposomes' anti-inflammatory effect combining in the same particles the MTX and the Colchicine (Col). Particles have a size around 100 nm with stability upon 4 days. The liposomes' encapsulation efficiency was ~ 28 % for MTX and ~ 33 % for COL with a ratio of 1:16. The anti-inflammatory effect was tested on the primary cell line (BMDM). Specifically, liposomes with MTX and Col were able to reduce the inflammation caused by the LPS. At the same time, they were able to modulate the foam cell marker (ABCA1), reflecting a reduction of the expression of IL-1? by 3-fold, IL-6 by 2-fold, and moderately of TNF-?. These results would suggest that combining the chemotherapeutic drugs in the liposomes could strongly reduce the inflammation modulating the disease progression. These data suggest that MTX and COL loaded nanoparticles could be the new strategy for the treatment of atherosclerosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
壮观小懒虫完成签到,获得积分10
3秒前
今后的应助被瘦瘦书本采纳,获得10
3秒前
大模型的应助被OVO采纳,获得10
4秒前
又是许想想完成签到,获得积分10
4秒前
Che完成签到 ,获得积分20
4秒前
4秒前
完美世界的应助被xx采纳,获得10
5秒前
情怀的应助被反派采纳,获得10
5秒前
飘逸的星星完成签到,获得积分10
6秒前
6秒前
淙淙完成签到,获得积分10
6秒前
yyy发布了新的文献求助10
7秒前
浪浪发布了新的文献求助10
7秒前
8秒前
8秒前
三五七言完成签到 ,获得积分10
8秒前
努力学习发布了新的文献求助10
8秒前
秋风的应助被MXX采纳,获得10
9秒前
beok完成签到,获得积分10
9秒前
10秒前
Jellyfish完成签到,获得积分10
10秒前
怕孤独的飞槐完成签到 ,获得积分10
10秒前
10秒前
罗喉完成签到 ,获得积分10
11秒前
11秒前
11秒前
积极的早晨完成签到,获得积分10
12秒前
yyy完成签到,获得积分10
12秒前
北辰小狼完成签到,获得积分10
13秒前
aqqq的应助被博修采纳,获得30
13秒前
搜集达人的应助被zzw采纳,获得10
13秒前
14秒前
15秒前
人咬兔子发布了新的文献求助10
15秒前
XZTX完成签到 ,获得积分10
15秒前
16秒前
舒适忆曼完成签到,获得积分10
16秒前
nell完成签到,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496